CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
This is the first update to the original CTS communication distributed on July 6th. As previously co...